Two-stage tuberculin skin testing in individuals with human immunodeficiency virus infection

C. T. Webster, F. M. Gordin, J. P. Matts, J. A. Korvick, C. Miller, K. Muth, L. S. Brown, C. L. Besch, J. O. Kumi, Catherine Salveson, A. Bincsik, K. Irvin, G. Maiatico

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

In this study we estimated occurrence of the booster effect in a population infected with the human immunodeficiency virus (HIV) and assessed the relation between the booster effect, T-lymphocyte CD4 cell counts, tuberculosis risk categories, and HIV exposure categories. Patients were recruited from 13 participating sites of the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). A two-stage tuberculin skin test was applied to 709 HIV-infected patients using the Mantoux method. An induration reading <5 mm on the first test and ≥ 5 mm on the second skin test defined the booster effect. Overall, 18 patients, or 2.7% (95% confidence interval, 1.6 to 4.2) experienced the booster effect. Boosted responses were seen in eight (2.1%) anergic patients, six (4.5%) nonanergic patients, and four (2.5%) with anergy status unknown. Boosting was noted in 1 of the 131 women enrolled. Age, race, CD4 cell count, injection drug use, anergy status, tuberculosis risk categories, and HIV exposure categories were not predictive of boosting. The booster effect occurs in a small percentage of HIV-infected patients tested, thus identifying small numbers of patients with latent tuberculosis infection. The two-stage procedure is probably of limited value in the diagnosis of latent tuberculosis in HIV-infected persons.

Original languageEnglish (US)
Pages (from-to)805-808
Number of pages4
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume151
Issue number3 I
StatePublished - 1995
Externally publishedYes

Fingerprint

Tuberculin
Virus Diseases
HIV
Skin
Latent Tuberculosis
CD4 Lymphocyte Count
Skin Tests
Tuberculosis
Tuberculin Test
Reading
Acquired Immunodeficiency Syndrome
Confidence Intervals
T-Lymphocytes
Injections
Research
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Webster, C. T., Gordin, F. M., Matts, J. P., Korvick, J. A., Miller, C., Muth, K., ... Maiatico, G. (1995). Two-stage tuberculin skin testing in individuals with human immunodeficiency virus infection. American Journal of Respiratory and Critical Care Medicine, 151(3 I), 805-808.

Two-stage tuberculin skin testing in individuals with human immunodeficiency virus infection. / Webster, C. T.; Gordin, F. M.; Matts, J. P.; Korvick, J. A.; Miller, C.; Muth, K.; Brown, L. S.; Besch, C. L.; Kumi, J. O.; Salveson, Catherine; Bincsik, A.; Irvin, K.; Maiatico, G.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 151, No. 3 I, 1995, p. 805-808.

Research output: Contribution to journalArticle

Webster, CT, Gordin, FM, Matts, JP, Korvick, JA, Miller, C, Muth, K, Brown, LS, Besch, CL, Kumi, JO, Salveson, C, Bincsik, A, Irvin, K & Maiatico, G 1995, 'Two-stage tuberculin skin testing in individuals with human immunodeficiency virus infection', American Journal of Respiratory and Critical Care Medicine, vol. 151, no. 3 I, pp. 805-808.
Webster, C. T. ; Gordin, F. M. ; Matts, J. P. ; Korvick, J. A. ; Miller, C. ; Muth, K. ; Brown, L. S. ; Besch, C. L. ; Kumi, J. O. ; Salveson, Catherine ; Bincsik, A. ; Irvin, K. ; Maiatico, G. / Two-stage tuberculin skin testing in individuals with human immunodeficiency virus infection. In: American Journal of Respiratory and Critical Care Medicine. 1995 ; Vol. 151, No. 3 I. pp. 805-808.
@article{7e426cc3202249b7a03b59484a81f378,
title = "Two-stage tuberculin skin testing in individuals with human immunodeficiency virus infection",
abstract = "In this study we estimated occurrence of the booster effect in a population infected with the human immunodeficiency virus (HIV) and assessed the relation between the booster effect, T-lymphocyte CD4 cell counts, tuberculosis risk categories, and HIV exposure categories. Patients were recruited from 13 participating sites of the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). A two-stage tuberculin skin test was applied to 709 HIV-infected patients using the Mantoux method. An induration reading <5 mm on the first test and ≥ 5 mm on the second skin test defined the booster effect. Overall, 18 patients, or 2.7{\%} (95{\%} confidence interval, 1.6 to 4.2) experienced the booster effect. Boosted responses were seen in eight (2.1{\%}) anergic patients, six (4.5{\%}) nonanergic patients, and four (2.5{\%}) with anergy status unknown. Boosting was noted in 1 of the 131 women enrolled. Age, race, CD4 cell count, injection drug use, anergy status, tuberculosis risk categories, and HIV exposure categories were not predictive of boosting. The booster effect occurs in a small percentage of HIV-infected patients tested, thus identifying small numbers of patients with latent tuberculosis infection. The two-stage procedure is probably of limited value in the diagnosis of latent tuberculosis in HIV-infected persons.",
author = "Webster, {C. T.} and Gordin, {F. M.} and Matts, {J. P.} and Korvick, {J. A.} and C. Miller and K. Muth and Brown, {L. S.} and Besch, {C. L.} and Kumi, {J. O.} and Catherine Salveson and A. Bincsik and K. Irvin and G. Maiatico",
year = "1995",
language = "English (US)",
volume = "151",
pages = "805--808",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "3 I",

}

TY - JOUR

T1 - Two-stage tuberculin skin testing in individuals with human immunodeficiency virus infection

AU - Webster, C. T.

AU - Gordin, F. M.

AU - Matts, J. P.

AU - Korvick, J. A.

AU - Miller, C.

AU - Muth, K.

AU - Brown, L. S.

AU - Besch, C. L.

AU - Kumi, J. O.

AU - Salveson, Catherine

AU - Bincsik, A.

AU - Irvin, K.

AU - Maiatico, G.

PY - 1995

Y1 - 1995

N2 - In this study we estimated occurrence of the booster effect in a population infected with the human immunodeficiency virus (HIV) and assessed the relation between the booster effect, T-lymphocyte CD4 cell counts, tuberculosis risk categories, and HIV exposure categories. Patients were recruited from 13 participating sites of the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). A two-stage tuberculin skin test was applied to 709 HIV-infected patients using the Mantoux method. An induration reading <5 mm on the first test and ≥ 5 mm on the second skin test defined the booster effect. Overall, 18 patients, or 2.7% (95% confidence interval, 1.6 to 4.2) experienced the booster effect. Boosted responses were seen in eight (2.1%) anergic patients, six (4.5%) nonanergic patients, and four (2.5%) with anergy status unknown. Boosting was noted in 1 of the 131 women enrolled. Age, race, CD4 cell count, injection drug use, anergy status, tuberculosis risk categories, and HIV exposure categories were not predictive of boosting. The booster effect occurs in a small percentage of HIV-infected patients tested, thus identifying small numbers of patients with latent tuberculosis infection. The two-stage procedure is probably of limited value in the diagnosis of latent tuberculosis in HIV-infected persons.

AB - In this study we estimated occurrence of the booster effect in a population infected with the human immunodeficiency virus (HIV) and assessed the relation between the booster effect, T-lymphocyte CD4 cell counts, tuberculosis risk categories, and HIV exposure categories. Patients were recruited from 13 participating sites of the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). A two-stage tuberculin skin test was applied to 709 HIV-infected patients using the Mantoux method. An induration reading <5 mm on the first test and ≥ 5 mm on the second skin test defined the booster effect. Overall, 18 patients, or 2.7% (95% confidence interval, 1.6 to 4.2) experienced the booster effect. Boosted responses were seen in eight (2.1%) anergic patients, six (4.5%) nonanergic patients, and four (2.5%) with anergy status unknown. Boosting was noted in 1 of the 131 women enrolled. Age, race, CD4 cell count, injection drug use, anergy status, tuberculosis risk categories, and HIV exposure categories were not predictive of boosting. The booster effect occurs in a small percentage of HIV-infected patients tested, thus identifying small numbers of patients with latent tuberculosis infection. The two-stage procedure is probably of limited value in the diagnosis of latent tuberculosis in HIV-infected persons.

UR - http://www.scopus.com/inward/record.url?scp=0028955973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028955973&partnerID=8YFLogxK

M3 - Article

C2 - 7881675

AN - SCOPUS:0028955973

VL - 151

SP - 805

EP - 808

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 3 I

ER -